Psychedelic Science Org UK

"Psychedelics could be for psychiatry what the microscope is for biology or the telescope for astronomy."

What is Psychedelic Science Org UK?

Psychedelic Science Org UK is a crowd-funding campaign that aims to raise funds for scientific research with psychedelic drugs, with a special focus on a clinical trial assessing the safety and efficacy of psilocybin as a treatment for depression.


Depression is a serious global problem. It’s the leading cause of disability worldwide, is linked to over half of all suicides, and affects some 350 million people. Worse still, the prevalence of depression is increasing; the World Health Organisation estimates that depression will become the leading overall contributor to the global burden of disease by 2030.


Psilocybin changes brain activity in a manner that is consistent with a large range of effective treatments for depression. More specifically, we found that circuits that are over-active and reinforced in depression become loosened and normalised under psilocybin. Psilocybin works to mimic some serotonin actions. That psilocybin does this, may explain why it may be useful in depression.

Help Us

All research depends on funding and if the funds aren’t there, the research simply can’t happen.So, if you believe in our vision and conviction to try and improve the lives of patients suffering from depression, then please give us your support! This is an incredibly worthwhile cause and we are perfectly placed to deliver on it.

Our Story

In 2012, Imperial College London were awarded a research grant from the UK government’s Medical Research Council (MRC) to set-up a clinical trial to investigate the antidepressant potential of psilocybin. The study is sponsored by Imperial College London and has ethical approval. The UK Home Office have licensed the importation and storage of the psilocybin that we will use.

Our Team

Key members
Dr Robin Carhart Harris (Founder)
Post-doctoral Researcher, Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London
Professor David Nutt
David Nutt (Founder) is currently the Edmond J Safra Professor of Neuropsychopharmacology and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences.
Dr James Rucker
Psychiatrist South London, Lecturer Kings College London,founder of the Maudsley Psychedelic Society


Messages of support

Research Background Videos

Latest Posts

  • Oct, 23

    The effects of psilocybin and MDMA on between-network resting state functional connectivity

    The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers Perturbing a system and observing the consequences is a classic scientific strategy for understanding a phenomenon. Psychedelic drugs perturb consciousness in a marked and novel way and thus are powerful tools for studying its mechanisms. In the present analysis, we […]

    Read more
    Oct, 23

    Cause for a re- think on drug models of psychosis and other psychiatric disorders

    Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders RL Carhart-Harris, S Brugger, DJ Nutt and JM Stone Despite the widespread application of drug modelling in psychiatric research, the relative value of different models has never been formally compared in the same analysis. Here we compared the […]

    Read more
  • Oct, 15

    How Psilocybin Improves Your Brain

    Psilocybin frees the brain from its rigid patterns and ego-driven assumptions, and allows the user to look at the world — and him or herself — from a whole new perspective. Many mushroom experiences also are accompanied by waves of good feelings and psychedelic visions of sound and color.   These results build on other […]

    Read more
    Oct, 15

    The Magic Effect Of Psilocybin Mushrooms

    “These are remarkable compounds, with I think remarkable implications, if we can understand how they work and why they work,” says Roland Griffiths, a scientist at Johns Hopkins University, where some of the world’s leading psychedelic research is taking place.   Psilocybin mushrooms provoke mystical experiences and spiritual journeys when the body breaks the chemical […]

    Read more
  • Sep, 25

    The administration of psilocybin to healthy hallucinogen experienced volunteers

    The administration of psilocybin to healthy,hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability This study sought to assess the tolerability of intravenously administered psilocybin in healthy, hallucinogen-experienced volunteers in a mock-magnetic resonance imaging environment as a preliminary stage to a controlled investigation using functional magnetic resonance imaging to explore […]

    Read more
    Sep, 25

    Neural correlates of the psychedelic state

    Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Psychedelic drugs have a long history of use in healing ceremonies, but despite renewed interest in their therapeutic potential, we continue to know very little about how they work in the brain. Here we used psilocybin, a classic psychedelic found in magic […]

    Read more
  • Sep, 25

    Homological scaffolds of brain functional networks

    Homological scaffolds of brain functional networks Networks, as efficient representations of complex systems, have appealed to scientists for a long time and now permeate many areas of science, including neuroimaging (Bullmore and Sporns 2009 Nat. Rev. Neurosci. 10, 186–198. (doi:10.1038/nrn2618)). Traditionally, the structure of complex networks has been studied through their statistical properties and metrics […]

    Read more
    Sep, 25

    A web based survey on mephedrone

    A web-based survey on mephedrone Mephedrone (4-methylmethcathinone) is a substituted cathinone with stimulant properties. The popularity of mephedrone in the UK rose sharply in 2009 after it became seen as a legal, cheap and easily available alternative to MDMA (ecstasy). Adverse events associated with its use, including a series of alleged deaths, attracted media attention […]

    Read more
  • Sep, 25

    LSD enhances suggestibility in healthy volunteers

    LSD enhances suggestibility in healthy volunteers Lysergic acid diethylamide (LSD) has a history of use as a psychotherapeutic aid in the treatment of mood disorders and addiction, and it was also explored as an enhancer of mind control. Objectives The present study sought to test the effect of LSD on suggestibility in a modern research […]

    Read more
    Sep, 25

    User perceptions of the benefits and harms of hallucinogenic drug use

    User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study   This study used a web-based questionnaire to investigate user perceptions of the benefits and harms of hallucinogenic drug use. Over 600 forms were submitted. Users were asked to comment on the acute and prolonged effects of different drugs and […]

    Read more